Early Career Researcher alert! Come along to our festival for the early career research community @UCL dedicated to breaking down barriers to achieving. From the @UCL_ACO and open to all @ucl and beyond
Adapt to Achieve Festival 22nd-26th November 2021
https://t.co/FBwROazAH3
@profgeraintrees Unlike, say, cancer screening, or court cases. Or - to get closer to the bone - oxbridge entrance exams; these things are absolute, and evidently always correct.
University rankings being an educated guess is clearly very, very bad.
Nice way to start the week. Ventricular ectopy mapped to basal inferior LV, suppressed and eliminated with first RF lesion. @DrAhranArnold@ImperialEP@Krishia_OB @BiosenseWebster
Completely agree. The UK research funding model systematically and deliberately fails to fund the full economic cost of research. And innovation primarily delivers impact not income - the wealth generation effects are in the broader economy around the university
Received copies of our textbook today. Covers all basic science, clinical and engineering aspects of pacing and defibrillation. Thanks @iefimov for inviting me to be part of this project. @SpringerNature@ImperialNHLI@BalvinderHanda
How fast are different countries vaccinating their population against COVID?
Israel: 11.6%
UK: 1.5%
US: 0.9%
Germany: 0.2%
World: 0.13%
→ Data for more countries you find in our COVID vaccine dataset here:
https://t.co/3imP7PqURn
Analysis of 2 years worth of Founder intros to VC’s: 90% US investors respond within 48 hrs; UK investors: polarised. 75% reply within 3 weeks or not at all. Small % respond within 48 hrs.
@elonmusk@wintonARK “As I look back on my life, I realize that every time I thought I was being rejected from something good, I was actually being re-directed to something better.”
Voice of British science fights for future of UK research & continued “UK involvement with the main EU research programmes after #Brexit — which is still up in the air” #horizoneu
https://t.co/5uVCwwuUMH
Interim analysis shows Beijing Institute of Biological Product’s vaccine (Sinophram) to have 86% efficacy against COVID-19 infection, 99% seroconversion rate of neutralizing antibody, and 100% effectiveness in preventing moderate and severe cases.
https://t.co/J6PeVHSM4n